This site is intended for Healthcare Professionals only.

European Medicines Agency backs gene therapy to treat rare bleeding disorder


Share post:

The European Union’s health regulator on Friday said it had recommended granting a conditional marketing authorization for a gene therapy by Australian drugmaker CSL Ltd and partner uniQure N.V. , to treat haemophilia B, a rare bleeding disorder which is caused by genetic anomalies.

About one in 40,000 people are affected by the inherited disorder, caused by a gene mutation that hampers the body’s ability to make clotting protein factor IX.

If approved, the treatment, branded Hemgenix, will be the first gene therapy in the European Union for the condition that is usually treated by regular injections of factor IX, the European Medicines Agency said.

CSL had acquired exclusive global rights to Hemgenix in May last year from uniQure N.V.

In November, the U.S. Food and Drug Administration approved Hemgenix for the treatment of rare genetic blood clotting disorder, followed by CSL Ltd setting the list price of the therapy at $3.5 million making it the world’s most expensive treatment.


Please enter your comment!
Please enter your name here

Current Issue March 2024

Related articles

Former NPA director Phil Galt named new Cegedim Rx UK managing director

Phill Galt replaces Adam Dennett who stepped down from the Cegedim Rx's leadership role after a successful ten-year...

Collaboration and partnership: The way forward with community pharmacy

Professor Mahendra G Patel elucidates how pharmacy professionals working in the multidisciplinary team can help to improve the...

Sigma Conference 2024: Sector says Pharmacy First won’t solve funding crisis

Demands for the next contractual framework include additional funding and write-off of any money that is owed, among...

Demand for private health cover surge amid NHS waiting list crisis

The UK health cover market was valued at £6.7 billion in 2022, marking a £385 million increase from...